An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 3, 2012, Pages 605-612

  O'Bryant, Cindy L ^a   Haluska, Paul ^b   Rosen, Lee ^c   Ramanathan, Ramesh K ^d   Venugopal, Balaji ^e   Leong, Stephen ^a   Boinpally, Ramesh ^f   Franke, Amy ^f   Witt, Karsten ^f   Evans, Jeffry ^e   Belani, Chandra ^d   Gail Eckhardt, S ^a   Ramalingam, Suresh ^d  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c Premiere Oncology   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f OSI PHARMACEUTICALS INC   (United States)

Author keywords

Erlotinib; Hepatic function; Pharmacokinetics; Protein binding; Safety

Indexed keywords

ERLOTINIB; OROSOMUCOID; SERUM ALBUMIN;

ACNE; ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLEAR CELL SARCOMA; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; ESOPHAGUS CANCER; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEAD AND NECK CANCER; HUMAN; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FAILURE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OVARY CANCER; PANCREAS CANCER; PAPULAR RASH; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PRURITUS; SKIN DISEASE; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; VAGINA CARCINOMA; VAGINAL SQUAMOUS CELL CARCINOMA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS; PROTEIN BINDING; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84859785784     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1733-6     Document Type: Article

References (28)

1. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132 (Pubitemid 41058344)
3. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966 (Pubitemid 46972777)
4. Tarceva [package insert] (2011) Genentech USA, Inc., South San Francisco, CA
5. van Erp NP, Gelderblom H, Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35:692-706
6. Hughes AN, O'Brien ME, Petty WJ et al (2009) Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 27:1220-1226
7. Lu JF, Eppler SM, Wolf J et al (2006) Clinical pharmacokinetics of erlotinib in patients with solid tumor and exposure-safety relationships in patients with non-small cell lug cancer. Clin Pharmacol Ther 80:136-145 (Pubitemid 44160689)
8. Guidance for industry pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. US department of health and human services food and drug administration center for drug evaluation and research (CDER) Center for biologics evaluation and research (CBER), May 2003
9. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK et al (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22(16):3238-3247 (Pubitemid 41103678)
10. Johnson JR, Cohen M, Sridhara R et al (2005) Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 11:6414-6421 (Pubitemid 41338977)
11. Pugh RH, Murray-Lyon IM, Dawson JL et al (1973) Transection of the esophagus for bleeding esophageal varices. Br J Surg 60:646-649
12. α-1 Acid Glycoprotein [Package Insert V4] (2003-2006). Roche Diagnostics Corporation, Indianapolis, IN
13. Hildalgo M, Siu LL, Neumanaitis J et al (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279 (Pubitemid 32591445)
14. Thomas F, Rochaix P, White-Koning M et al (2009) Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer 45:2316-2323
15. Rudin CM, Liu W, Desai A et al (2008) Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26:1119-1127
16. Ling J, Johnson KA, Miao Z et al (2006) Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 34:420-426 (Pubitemid 43290900)
17. Miller AA, Murry DJ, Owzar K et al (2007) Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 25:3055-3060 (Pubitemid 47218052)
18. Herbst RS, Prager D, Hermann R et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899
19. Philip PA, Mahoney MR, Allmer C et al (2005) Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23:6657-6663 (Pubitemid 46190260)
20. Philip PA, Mahoney MR, Allmer C et al (2006) Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24:3069-3074 (Pubitemid 46638942)
21. Forsythe B, Faulkner K (2004) Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in non-small-cell lung cancer. Drug Saf 27:1081-1092 (Pubitemid 39647851)
22. Dragovich T, McCoy S, Fenoglio-Preiser CM et al (2006) Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 24:4922-4927 (Pubitemid 46630921)
23. Ramanarayanan J, Scarpace SL (2007) Acute drug induced hepatitis due to erlotinib. JOP J Pancreas (Online) 8:39-43 (Pubitemid 46157767)
24. Saif MW (2008) Erlotinib-induced acute hepatitis in a patient with pancreatic cancer. Clin Adv Hematol Oncol 6:191-199
25. Ho C, Davis J, Anderson F, Bebb G, Murray N (2005) Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. J Clin Oncol 23:8531-8533
26. Carlini P, Papaldo P, Fabi A et al (2006) Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450? J Clin Oncol 24:e60-e61
27. Patel H, Egorin MJ, Remick SC et al (2004) Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): implications for chemotherapy dosing [abstract]. Proc Am Soc Clin Oncol 22:6051
28. Saif MW (2008) Hepatic failure and hepatorenal syndrome secondary to erlotinib. Safety reminder. J Pancreas (Online) 9:748-752